ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. EOSE
2. DLR
3. AVAV
4. SPY
5. VSH
6. MU
7. ENPH
8. BAC
9. CNS
10. CMCSA

Go back to ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 17,644       

ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 17,644       

Daiichi Sankyo Co Limited Sponsored ADR (AMEX: DSNKY) Delayed: 16.23 --0 (-0%)
Previous Close $16.23    52 Week High $26.24 
Open $16.23    52 Week Low $18.86 
Day High $16.23    P/E N/A 
Day Low $16.23    EPS $0.00 
Volume 100